| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Miguel Medina | Q37835217 |
| P2860 | cites work | Protein phosphatase 2A dysfunction in Alzheimer's disease | Q21090465 |
| A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease | Q21146622 | ||
| A protein factor essential for microtubule assembly | Q22010837 | ||
| Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines | Q24598853 | ||
| Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib | Q24610904 | ||
| Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease | Q24657243 | ||
| Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum | Q24657634 | ||
| New Features about Tau Function and Dysfunction | Q26750922 | ||
| Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits | Q27314989 | ||
| Tau Biology and Tau-Directed Therapies for Alzheimer's Disease | Q28071398 | ||
| Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17 | Q28274687 | ||
| A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy | Q50479057 | ||
| Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. | Q52200995 | ||
| Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. | Q53434499 | ||
| A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer's Disease | Q58202813 | ||
| Pathogenesis of the tauopathies | Q84590188 | ||
| Stem-cell discovery platforms yield first clinical candidates | Q86040750 | ||
| A phase 3 trial of IV immunoglobulin for Alzheimer disease | Q38378475 | ||
| Tau immunotherapy for Alzheimer's disease | Q38407801 | ||
| Tau Immunotherapy | Q38628672 | ||
| Emergence of BCR-ABL kinase domain mutations associated with newly diagnosed chronic myeloid leukemia: a meta-analysis of clinical trials of tyrosine kinase inhibitors | Q41537144 | ||
| A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment | Q43958437 | ||
| Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. | Q44824216 | ||
| Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial | Q45328463 | ||
| A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. | Q45970893 | ||
| Human secreted tau increases amyloid-beta production | Q46807999 | ||
| Tau immunization: a cautionary tale? | Q46828505 | ||
| Atypical, non-standard functions of the microtubule associated Tau protein | Q47145684 | ||
| Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial. | Q47147322 | ||
| Developing Disease-Modifying Treatments in Alzheimer's Disease - A Perspective from Roche and Genentech | Q47357624 | ||
| Characterization of isolated tau-reactive antibodies from the IVIG product, plasma of patients with Alzheimer's disease and cognitively normal individuals. | Q47387363 | ||
| Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice | Q47547728 | ||
| Tau-based therapies in neurodegeneration: opportunities and challenges | Q47689697 | ||
| Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies | Q47947288 | ||
| The primary structure and heterogeneity of tau protein from mouse brain | Q48122949 | ||
| Hyperphosphorylation determines both the spread and the morphology of tau pathology | Q48476058 | ||
| Protein changes in senile dementia | Q48522695 | ||
| Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial | Q48905569 | ||
| Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy | Q29417026 | ||
| Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology | Q29617284 | ||
| Amyloid-β oligomers induce tau-independent disruption of BDNF axonal transport via calcineurin activation in cultured hippocampal neurons | Q30542949 | ||
| Single-molecule tracking of tau reveals fast kiss-and-hop interaction with microtubules in living neurons | Q30597670 | ||
| Roles of tau protein in health and disease | Q33559303 | ||
| Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial | Q34031302 | ||
| A phase II trial of tideglusib in Alzheimer's disease | Q34042842 | ||
| Epothilone D Improves Microtubule Density, Axonal Integrity, and Cognition in a Transgenic Mouse Model of Tauopathy | Q34218584 | ||
| Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study. | Q34296827 | ||
| Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease | Q34456081 | ||
| Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy | Q34973787 | ||
| Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease | Q34995116 | ||
| Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration | Q35327851 | ||
| The non-fluent/agrammatic variant of primary progressive aphasia | Q35992776 | ||
| Tau protein function in living cells | Q36216609 | ||
| The GSK3 hypothesis of Alzheimer's disease | Q37035378 | ||
| Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models | Q37048487 | ||
| Tau-based treatment strategies in neurodegenerative diseases | Q37215861 | ||
| Tau phosphorylation: the therapeutic challenge for neurodegenerative disease | Q37402114 | ||
| Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. | Q37511619 | ||
| PERK activation mitigates tau pathology in vitro and in vivo | Q37672742 | ||
| Amyloid-beta immunotherapy: the hope for Alzheimer disease? | Q37679265 | ||
| Fyn kinase inhibition as a novel therapy for Alzheimer's disease | Q37689640 | ||
| The role of extracellular Tau in the spreading of neurofibrillary pathology. | Q37734856 | ||
| Recent developments in tau-based therapeutics for neurodegenerative diseases | Q37813731 | ||
| "Lest we forget you--methylene blue...". | Q37840811 | ||
| Modulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies | Q37946881 | ||
| Progress and developments in tau aggregation inhibitors for Alzheimer disease | Q38088711 | ||
| Tau pathology and neurodegeneration | Q38107632 | ||
| New insights into the role of glycogen synthase kinase-3 in Alzheimer's disease. | Q38149943 | ||
| Further understanding of tau phosphorylation: implications for therapy. | Q38306065 | ||
| Intravenous immunoglobulin in neurology--mode of action and clinical efficacy | Q38308436 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nerve tissue protein | Q6996861 |
| tauopathy | Q2397106 | ||
| cytoskeletal proteins | Q66563066 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P577 | publication date | 2018-04-11 | |
| P1433 | published in | International Journal of Molecular Sciences | Q3153277 |
| P1476 | title | An Overview on the Clinical Development of Tau-Based Therapeutics. | |
| P478 | volume | 19 |
| Q90999408 | A MultiTEP platform-based epitope vaccine targeting the phosphatase activating domain (PAD) of tau: therapeutic efficacy in PS19 mice |
| Q92007636 | Advances and considerations in AD tau-targeted immunotherapy |
| Q90003697 | Ageing as a risk factor for neurodegenerative disease |
| Q91924117 | Allosteric Modulators of Potential Targets Related to Alzheimer's Disease: a Review |
| Q60530541 | Amyloid, tau, pathogen infection and antimicrobial protection in Alzheimer's disease -conformist, nonconformist, and realistic prospects for AD pathogenesis |
| Q92929332 | Antioxidant and Anti-inflammatory Mechanisms of Neuroprotection by Ursolic Acid: Addressing Brain Injury, Cerebral Ischemia, Cognition Deficit, Anxiety, and Depression |
| Q61809000 | Bivalent Ligands for Protein Degradation in Drug Discovery |
| Q92881963 | Computer-Aided Drug Design of β-Secretase, γ-Secretase and Anti-Tau Inhibitors for the Discovery of Novel Alzheimer's Therapeutics |
| Q92680738 | Copper(II) Coordination Abilities of the Tau Protein's N-Terminus Peptide Fragments: A Combined Potentiometric, Spectroscopic and Mass Spectrometric Study |
| Q90283590 | Current and Future Treatments in Alzheimer Disease: An Update |
| Q90637527 | Diabetes as a risk factor for Alzheimer's disease in the Middle East and its shared pathological mediators |
| Q92787966 | Enhancement of tripartite synapses as a potential therapeutic strategy for Alzheimer's disease: a preclinical study in rTg4510 mice |
| Q64248565 | Exploring the Pathogenesis of Alzheimer Disease in Basal Forebrain Cholinergic Neurons: Converging Insights From Alternative Hypotheses |
| Q91635049 | GSK3β and Tau Protein in Alzheimer's Disease and Epilepsy |
| Q98177882 | Galectin-3 Secreted by Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Reduces Aberrant Tau Phosphorylation in an Alzheimer Disease Model |
| Q92761855 | Neuroprotective Approach of Anti-Cancer Microtubule Stabilizers Against Tauopathy Associated Dementia: Current Status of Clinical and Preclinical Findings |
| Q94460595 | O-GlcNAcylation and its role in the immune system |
| Q64119235 | Precision Medicine for Frontotemporal Dementia |
| Q96765537 | Prolonged tau clearance and stress vulnerability rescue by pharmacological activation of autophagy in tauopathy neurons |
| Q61448084 | Protein -GlcNAcylation in Cardiac Pathologies: Past, Present, Future |
| Q92604912 | Sex modulates the ApoE ε4 effect on brain tau deposition measured by 18F-AV-1451 PET in individuals with mild cognitive impairment |
| Q64054848 | Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models |
| Q57472231 | Weak power frequency magnetic fields induce microtubule cytoskeleton reorganization depending on the epidermal growth factor receptor and the calcium related signaling |
| Q89805038 | Xenobiotics, Trace Metals and Genetics in the Pathogenesis of Tauopathies |
Search more.